[Heart failure associated with ischemic cardiomyopathy].
Ogawa
Takayuki
T
Division of Cardiology, Department of Internal Medicine, The Jikei University School of Medicine.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D015906:Angioplasty, Balloon, Coronary; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002304:Cardiac Pacing, Artificial / Q000379:methods; D006348:Cardiac Surgical Procedures; D001026:Coronary Artery Bypass; D017147:Defibrillators, Implantable; D006333:Heart Failure / Q000209:etiology* / Q000503:physiopathology / Q000517:prevention & control / Q000628:therapy; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use; D017202:Myocardial Ischemia / Q000209:etiology* / Q000503:physiopathology / Q000517:prevention & control / Q000628:therapy; D017682:Myocardial Stunning / Q000150:complications / Q000503:physiopathology / Q000628:therapy; D055502:Secondary Prevention; D020257:Ventricular Remodeling
D000319:Adrenergic beta-Antagonists; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000451:Mineralocorticoid Receptor Antagonists